<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01221610</url>
  </required_header>
  <id_info>
    <org_study_id>C1003</org_study_id>
    <nct_id>NCT01221610</nct_id>
  </id_info>
  <brief_title>BIOLUX P-I First in Man Study</brief_title>
  <official_title>A Prospective, Multi-centre, Randomized Controlled, First in Man Study to Assess the Safety and Performance of the Passeo-18 Lux Paclitaxel Releasing PTA Balloon Catheter vs. the Uncoated Passeo 18 Balloon Catheter in Patients With Stenosis and Occlusion of the Femoropopliteal Arteries (BIOLUX P-I).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multi-centre, randomized controlled, First in Man study to assess the safety
      and performance of the coated Passeo-18 Lux Paclitaxel releasing PTA Balloon Catheter vs. an
      uncoated balloon catheter in patients with stenosis and occlusion of the femoropopliteal
      arteries.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the 6 months late lumen loss in the target lesion measured by quantitative vascular angiography (QVA).</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>6 months binary restenosis rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 months and 12 months TLR rate</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 months and 12 months change in mean ABI</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 months and 12 months change in Rutherford class</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Event rate at 6 and 12 months (procedure- or device-related death or amputation, target lesion thrombosis and clinically driven TLR)</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Arteriosclerosis</condition>
  <condition>Vascular Disease</condition>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>Drug Releasing Balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Passeo-18 Lux Drug Releasing Balloon catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard PT A (POBA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Uncoated Passeo-18 PTA catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Passeo-18 Lux DRB</intervention_name>
    <arm_group_label>Drug Releasing Balloon</arm_group_label>
    <other_name>Passeo-18 Lux Drug Releasing Balloon catheter</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard PTA (POBA)</intervention_name>
    <arm_group_label>Standard PT A (POBA)</arm_group_label>
    <other_name>Passeo-18 PTA catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 50 years,

          2. Informed consent signed by patient prior to randomization

          3. Single or sequential de novo or restenotic lesions (stenosis ≥ 70% diameter reduction
             or occlusion) in the femoropopliteal arteries ≥ 30 mm and ≤ 200 mm long

          4. Rutherford Class 2 - 5 in the target limb

          5. Reference Vessel Diameter (RVD) 3 - 7 mm, based on visual estimation

          6. Inflow free from flow-limiting lesion (&lt; 50% stenosis) confirmed by angiography.
             Patients with flow-limiting inflow lesions (&gt; 50% stenosis) can be included if lesion
             has been treated successfully before the index procedure

          7. At least one non-occluded crural vessel (eg without significant stenosis) with
             angiographically documented run-off to the foot

          8. Successful wire crossing of the lesion

          9. Willingness to comply with all specified follow-up evaluations

         10. Male or negative pregnancy test of women in childbearing age

        Exclusion Criteria:

          1. Co-morbid conditions limiting life expectancy ≤ 1 year

          2. Patient currently participating in another clinical trial

          3. Lesions which are untreatable with PTA or other interventional techniques

          4. The target stenosis is located distal to a stenosis ≥ 50% that cannot be pre-treated
             because the drug coating could get lost during crossing the proximal lesion

          5. Thrombus in the target vessel, documented by angiography

          6. Target lesion is severely calcified, documented by angiography

          7. Prior bypass surgery of target vessel

          8. Previously implanted stent in the target lesion

          9. Treatment of bifurcation required

         10. Planned amputation of the target limb

         11. Flow-limiting (&gt; 50% DS) Inflow lesion proximal to target lesion, left untreated

         12. Failure to obtain &lt;30% residual stenosis in a pre-existing haemodynamically
             significant (&gt;50% DS) inflow lesion in the ipsilateral iliac or proximal SFA. (DEB or
             DES not allowed for the treatment of inflow lesion)

         13. Additional hemodynamically relevant proximal and distal lesions with stenosis ≥ 50 %,
             except iliac arteries, are excluded. Iliac artery lesion treatments have to be
             successful with a residual stenosis ≤ 30 %

         14. Haemorrhagic diathesis or another disorder such as gastrointestinal ulceration or
             cerebral circulatory disorders which restrict the use of platelet aggregation
             inhibitor therapy and anticoagulation therapy

         15. Phenprocoumon intake

         16. Impaired renal function (creatinine ≥ 2.0 - 2.5 mg/dl), according to investigator
             assessment

         17. Known allergy to contrast media that cannot be adequately controlled with
             pre-medication

         18. Allergy, intolerance or hypersensitivity to Paclitaxel structurally or related
             compounds and/or to the delivery matrix n-Butyryl tri-nhexyl citrate (BTHC)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dierk Scheinert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Park-Krankenhaus Leipzig GmbH, Leipzig, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AKH Wien, Kardiovaskuläre und Interventionelle Radiologie</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gefaesszentrum Berlin, Medizinische Klinik, Ev. Krankenhaus Königin Elisabeth Herzberge</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkkrankenhaus Leipzig Südost GmbH</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut für diagnostische und interventionelle Radiologie, Klinikum Rosenheim</name>
      <address>
        <city>Rosenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2010</study_first_submitted>
  <study_first_submitted_qc>October 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2010</study_first_posted>
  <last_update_submitted>February 6, 2015</last_update_submitted>
  <last_update_submitted_qc>February 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stenosis</keyword>
  <keyword>Occlusions</keyword>
  <keyword>SFA</keyword>
  <keyword>PTA</keyword>
  <keyword>POBA</keyword>
  <keyword>DRB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

